John Zajecka to Secondary Prevention
This is a "connection" page, showing publications John Zajecka has written about Secondary Prevention.
Connection Strength
0.445
-
Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020 03 01; 77(3):237-245.
Score: 0.155
-
Residual symptoms in major depressive disorder: prevalence, effects, and management. J Clin Psychiatry. 2013 Apr; 74(4):407-14.
Score: 0.096
-
SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004; 65 Suppl 17:11-8.
Score: 0.050
-
Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:42-7.
Score: 0.044
-
Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry. 1999 Jun; 60(6):389-94.
Score: 0.037
-
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
Score: 0.020
-
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007 Jul; 68(7):1014-23.
Score: 0.016
-
Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry. 2007 Mar; 68(3):e06.
Score: 0.016
-
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003 Jul; 160(7):1263-71.
Score: 0.012